National Bank of Canada’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

National Bank of Canada’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5	Closed	-$21	–	2894
2023 Q1	$21	Hold	5	–	–	﹤0.01%	2676
2022 Q4	$30	Hold	5	–	–	﹤0.01%	2733
2022 Q3	$0	Hold	5	–	–	﹤0.01%	3004
2022 Q2	$0	Sell	5 -5,000	-100%	-$25.6K	﹤0.01%	3117
2022 Q1	$23K	Buy	5,005 +5,000	+100,000%	+$14.9K	﹤0.01%	2143
2021 Q4	$0	Buy	+5	New	+$12	﹤0.01%	2868

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

National Bank of Canada's CTIC Position: Q2 2023 in Review

National Bank of Canada sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 5 shares — an estimated $21 sold.

National Bank of Canada first reported a position in CTIC in Q4 2021 and held it in 6 quarters. The position peaked at $23K in Q1 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

National Bank of Canada reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
National Bank of Canada sold 5 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $21.
National Bank of Canada first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2021 and held it in 6 quarters.
National Bank of Canada's CTI BioPharma Corp. (DE) Common Stock position peaked at $23K in Q1 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on National Bank of Canada's 13F filing for Q2 2023, filed 26 Jul 2023.